All In Biotech

Drug Trial Radar · NCT06942793

A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients

A Phase 3, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

396

Planned (sponsor's estimate)

Start

May 20, 2025

Primary completion

Oct 20, 2025

Study completion Nov 15, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, multicenter, randomized, double-masked, Active-controlled design. The aims to confirm previous findings of the efficacy and safety of CsA-PG Ophthalmic Gel by comparing it to CsA Ophthalmic Gel for treating dry eye symptoms.

Conditions

  • Dry Eye Disease

Interventions

  • CsA-PG Ophthalmic GelDrug

    Administer to eyes

  • CsA Ophthalmic GelDrug

    Administer to eyes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eye Dryness Score(EDS)Time frame: 84 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.